Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Ironwood Pharmaceuticals Inc

Healthcare US IRWD

3.4USD
0.16(4.94%)

Last update at 2026-06-04T20:25:00Z

Day Range

3.253.46
LowHigh

52 Week Range

5.8315.70
LowHigh

Fundamentals

  • Previous Close 3.24
  • Market Cap934.67M
  • Volume1870474
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA121.50M
  • Revenue TTM413.55M
  • Revenue Per Share TTM2.65
  • Gross Profit TTM 366.33M
  • Diluted EPS TTM-6.71

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 252.42M 200.66M 108.86M 58.94M -282.36800M
Minority interest - - - - -
Net income 175.06M 528.45M 106.18M -15.31400M -282.36800M
Selling general administrative 115.99M 111.13M 140.00M 172.45M 241.29M
Selling and marketing expenses - - - - -
Gross profit 410.60M 413.75M 386.39M 404.54M 313.89M
Reconciled depreciation 1.42M 1.52M 3.56M 5.58M 14.22M
Ebit 250.34M 232.26M 142.94M 120.12M -102.01700M
Ebitda 259.84M 232.94M 159.85M 120.42M -93.90600M
Depreciation and amortization 9.50M 0.68M 16.91M 0.30M 8.11M
Non operating income net other 9.68M -0.45200M -4.60100M -24.57800M -5.75200M
Operating income 250.34M 232.26M 142.94M 120.12M -238.89200M
Other operating expenses 160.26M 181.54M 231.20M 311.37M 448.66M
Interest expense 7.60M 31.15M 29.48M 36.60M 34.73M
Tax provision 77.36M -327.79100M 2.69M - -
Interest income 9.50M 0.73M 1.50M 2.86M 2.99M
Net interest income 1.90M -30.42400M -27.97400M -33.74000M -34.73300M
Extraordinary items - - - -37.43800M -88.22200M
Non recurring - - 15.38M 3.62M 167.69M
Other items - - - - -
Income tax expense 77.36M -327.79100M 2.69M 74.26M -5.75200M
Total revenue 410.60M 413.75M 389.52M 428.41M 346.64M
Total operating expenses 160.26M 181.54M 228.06M 287.49M 415.90M
Cost of revenue 0.00000M 0.00000M 3.14M 23.88M 32.75M
Total other income expense net 2.08M -31.60200M -34.07900M -61.18000M -145.61800M
Discontinued operations - - - -37.43800M -88.22200M
Net income from continuing ops 175.06M 528.45M 106.18M 58.94M -282.36800M
Net income applicable to common shares 175.06M 528.45M 106.18M 21.50M -282.36800M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 471.07M 1100.52M 1126.93M 559.24M 402.75M
Intangible assets 3.68M - - - -
Earning assets - - - - -
Other current assets 12.01M 7.71M 11.05M 10.92M 11.94M
Total liab 817.37M 448.14M 521.02M 496.60M 496.00M
Total stockholder equity -346.29500M 652.38M 605.91M 62.64M -93.25100M
Deferred long term liab - - - 12.09M 24.26M
Other current liab 64.34M 21.98M 1.32M 0.54M 33.42M
Common stock 0.16M 0.15M 0.16M 0.16M 0.16M
Capital stock 0.16M 0.15M 0.16M 0.16M 0.16M
Retained earnings -1698.61500M -696.37600M -937.60800M -1466.05600M -1572.23200M
Other liab - 9.77M 3.50M 13.31M 24.99M
Good will - - - 0.79M 0.79M
Other assets 0.00000M 299.58M 358.78M 54.47M 64.94M
Cash 92.15M 656.20M 620.13M 362.56M 177.02M
Cash and equivalents - - - - -
Total current liabilities 276.10M 25.52M 161.70M 32.71M 40.93M
Current deferred revenue 1.24M - 39.46M 28.38M 0.88M
Net debt 623.38M -240.28800M -144.32700M 91.14M 254.20M
Short term debt 202.69M 3.06M 119.98M 3.13M 1.15M
Short long term debt 199.56M - 116.86M - -
Short long term debt total 715.54M 415.92M 475.80M 453.70M 431.22M
Other stockholder equity 1355.19M 1348.60M 1543.36M 1528.54M 1478.82M
Property plant equipment - 6.29M 22.93M 8.93M 12.43M
Total current assets 233.29M 780.63M 745.23M 495.84M 306.85M
Long term investments - 14.59M 24.00M 36.47M 63.96M
Net tangible assets - 668.98M 605.91M 82.96M -71.95400M
Short term investments - - - - -
Net receivables 129.12M 115.46M 114.04M 122.35M 117.25M
Long term debt 498.31M 396.25M 337.33M 430.26M 407.99M
Inventory 0.00000M 1.25M - 0.00000M 0.65M
Accounts payable 7.83M 0.48M 0.94M 0.66M 5.49M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -3.03100M - - -11.80500M -10.08200M
Additional paid in capital - - - - -
Common stock total equity - 0.15M 0.16M 0.16M 0.16M
Preferred stock total equity - - - - -
Retained earnings total equity - -696.37600M -937.60800M -1466.05600M -1572.23200M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 3.61M 15.92M 25.48M 37.11M 64.94M
Deferred long term asset charges - - - - -
Non current assets total 237.78M 319.89M 381.70M 63.40M 95.90M
Capital lease obligations 17.67M 19.66M 21.61M 23.45M 23.23M
Long term debt total - 396.25M 337.33M 430.26M 407.99M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.13600M -0.26500M -1.84200M -11.14400M 95.92M
Change to liabilities -7.93000M 10.08M -7.55200M -33.18300M 8.96M
Total cashflows from investing activities -0.13600M -0.26500M -1.84200M -11.14400M 88.87M
Net borrowings -120.69900M -120.69900M -120.69900M 16.25M -1.82400M
Total cash from financing activities -237.55300M -4.55000M 18.55M -1.18500M 30.07M
Change to operating activities 2.94M 12.66M 2.72M 0.72M -1.56700M
Net income 175.06M 528.45M 106.18M 21.50M -282.36800M
Change in cash 36.07M 257.08M 185.54M -1.60400M 48.06M
Begin period cash flow 621.86M 364.78M 179.24M 180.85M 132.79M
End period cash flow 657.94M 621.86M 364.78M 179.24M 180.85M
Total cash from operating activities 273.76M 261.89M 168.84M 10.72M -70.88200M
Issuance of capital stock - - - - -
Depreciation 1.42M 1.52M 3.56M 5.58M 14.22M
Other cashflows from investing activities - - - -3.95500M 1.56M
Dividends paid 111.16M - - - -
Change to inventory 0.00000M 0.00000M 0.65M 0.72M -0.80600M
Change to account receivables 7.99M 7.71M 4.09M -68.89300M 1.21M
Sale purchase of stock -126.39400M -24.13100M 18.55M 13.60M 32.06M
Other cashflows from financing activities 111.16M 19.58M 18.55M 155.22M 31.90M
Change to netincome 91.49M -321.69200M 19.47M 90.00M 104.43M
Capital expenditures 0.14M 0.27M 1.84M 7.19M 8.62M
Change receivables 7.99M 7.71M 4.09M -68.89300M 1.21M
Cash flows other operating 3.87M 11.88M 20.17M -23.87100M 66.03M
Exchange rate changes - - - - -
Cash and cash equivalents changes 36.07M 257.08M 185.54M -1.60400M 48.06M
Change in working capital 2.82M 17.73M -0.94100M -99.99300M 7.62M
Stock based compensation 27.05M 22.28M 31.18M 31.28M 43.98M
Other non cash items 1.67M 25.21M 22.26M 16.42M -13.44400M
Free cash flow 273.63M 261.63M 166.99M 3.54M -79.50300M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
IRWD
Ironwood Pharmaceuticals Inc		 0.16 4.94% 3.40 - 12.33 2.79 2.59 4.19 -2.0077
ZTS
Zoetis Inc		 1.93 2.49% 79.52 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 1.31 4.22% 32.32 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 14.53 9.74% 163.71 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 -0.34 0.83% 40.58 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Ironwood Pharmaceuticals Inc

100 Summer Street, Boston, MA, United States, 02110

Key Executives

Name Title Year Born
Ms. Julie H. McHugh Exec. Chairman 1964
Mr. Thomas A. McCourt CEO & Director 1957
Mr. Sravan Kumar Emany Sr. VP, Principal Financial Officer & CFO 1978
Mr. Jason Rickard Sr. VP & COO 1971
Mr. John Minardo Sr. VP, Chief Legal Officer & Sec. 1976
Dr. Michael Shetzline M.D., Ph.D. Chief Medical Officer, Sr. VP and Head of Research & Drug Devel. 1959
Mr. Ronald Silver Corp. Controller & Principal Accounting Officer 1982
Mr. Marcel Moulaison VP of Technical Operations NA
Ms. Beth Calitri Head of Corp. Communications & Media Relations NA
Mr. Mike Nanfito VP of Sales & Sales Excellence NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions